Form 4: Edwards Lifesciences CEO Bernard Zovighian Reports Changes in Beneficial Ownership

CEO Bernard Zovighian reports transactions involving Edwards Lifesciences Corp stock, including acquisitions, disposals, and grants of stock options and restricted stock units.

Summary

• On May 7, 2025, Bernard Zovighian disposed of 4,253 shares of Edwards Lifesciences Corp common stock at a price of $74.92.
• On May 8, 2025, Zovighian acquired 43,550 shares of common stock.
• Also on May 8, 2025, Zovighian disposed of 4,122 shares of common stock through a gift.
• Zovighian was granted 244,400 employee stock options exercisable beginning one month after the grant date and expiring on May 7, 2032.
• He also received 43,550 performance rights that will vest on May 8, 2028, depending on the achievement of certain performance goals.
• Following these transactions, Zovighian directly owns 92,422.5511 shares of common stock and indirectly owns 17,076 shares through a trust and 3,605.8487 shares through a 401(k).

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management interests with shareholder value. The grants of stock options and performance rights are a positive sign.

Positives

• The grant of stock options and performance rights to the CEO aligns his interests with those of the shareholders.
• The vesting of performance rights is tied to the achievement of specific performance goals, incentivizing the CEO to drive company performance.

Future Outlook

The restricted stock units are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. The options are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. The performance rights are scheduled to vest on May 8, 2028, depending on the achievement of certain performance goals over a three-year performance period.

Industry Context

Executive compensation through stock options and restricted stock units is a common practice in the medical device industry to align management's interests with those of shareholders and incentivize long-term performance.

Comparison to Industry Standards

• Companies like Medtronic and Abbott also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and performance metrics associated with these grants are typically aligned with industry best practices to ensure that executives are rewarded for achieving specific financial and strategic goals.

Stakeholder Impact

• Shareholders: The grants of stock options and performance rights align management's interests with shareholder value.
• Employees: The Long-Term Stock Incentive Compensation Program can motivate employees.

Key Dates

Keywords

Form 4, Beneficial Ownership, Edwards Lifesciences, Zovighian, Stock Options, Performance Rights, Common Stock